文献速递产科母胎医学

联合抗逆转录病毒治疗与妊娠期高血压疾病

Combination Antiretroviral Therapy and Hypertensive Disorders of Pregnancy.
PubMed 文献 · Obstet Gynecol · 2019-01-01

回顾性队列研究比较HIV感染联合抗逆转录病毒治疗(ART)孕妇与无HIV孕妇的妊娠期高血压疾病发生率,并评估ART方案及启动时机与妊娠期高血压疾病的关联。HIV感染孕妇与无HIV孕妇风险相似(29% vs 30%,aRR 0.9,95%CI 0.6-1.3);含整合酶链转移抑制剂方案较含蛋白酶抑制剂方案妊娠期高血压疾病风险升高(25% vs 10%,aRR 2.8,95%CI 1.5-5.1)。

要点

  • HIV感染联合ART孕妇与无HIV孕妇妊娠期高血压疾病风险无显著差异(29% vs 30%,aRR 0.9,95%CI 0.6-1.3)。
  • 含整合酶链转移抑制剂方案较含蛋白酶抑制剂方案妊娠期高血压疾病风险升高(25% vs 10%,aRR 2.8,95%CI 1.5-5.1)。
  • ART启动时机与妊娠期高血压疾病无显著关联,也未显著改变ART方案与妊娠期高血压疾病的关联。

核心结论

  • HIV感染联合ART孕妇与无HIV孕妇的妊娠期高血压疾病总体风险相似。
  • 含整合酶链转移抑制剂方案较含蛋白酶抑制剂方案妊娠期高血压疾病更常见,需更大样本队列进一步评估。

研究设计与样本

  • 回顾性队列研究,基于单一三级医院既有数据库的两个重叠妊娠队列:2016-2018年所有分娩孕妇(队列1)和2011-2018年所有HIV感染分娩孕妇(队列2)。
  • 队列1比较HIV感染与无HIV孕妇,队列2评估ART方案(含整合酶链转移抑制剂、含蛋白酶抑制剂或含非核苷类逆转录酶抑制剂)及启动时机。
  • 采用改良泊松回归伴稳健误差方差估计风险比(RR),并在队列2 HIV感染孕妇中检验ART方案与启动时机的统计交互作用。

主要发现

  • 队列1中HIV感染孕妇80例与无HIV孕妇3464例比较,妊娠期高血压疾病风险无差异(29% vs 30%,调整RR 0.9,95%CI 0.6-1.3)。
  • 队列2中265例HIV感染孕妇,含整合酶链转移抑制剂方案较含蛋白酶抑制剂方案妊娠期高血压疾病风险升高(25% vs 10%,调整RR 2.8,95%CI 1.5-5.1)。
  • 含整合酶链转移抑制剂方案较含蛋白酶抑制剂方案妊娠期高血压风险升高(20% vs 8%,调整RR 2.8,95%CI 1.3-5.9)。
  • ART启动时机与妊娠期高血压疾病无显著关联,也未显著改变ART方案与妊娠期高血压疾病结局的关联。

关键数值与推荐

  • 队列1:HIV感染孕妇妊娠期高血压疾病29% vs 无HIV孕妇30%(调整RR 0.9,95%CI 0.6-1.3)。
  • 队列2:含整合酶链转移抑制剂方案妊娠期高血压疾病25% vs 含蛋白酶抑制剂方案10%(调整RR 2.8,95%CI 1.5-5.1)。
  • 队列2:含整合酶链转移抑制剂方案妊娠期高血压20% vs 含蛋白酶抑制剂方案8%(调整RR 2.8,95%CI 1.3-5.9)。
  • ART启动时机与妊娠期高血压疾病无显著关联,且未显著改变ART方案与妊娠期高血压疾病结局的关联。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为含整合酶链转移抑制剂方案较含蛋白酶抑制剂方案妊娠期高血压疾病更常见,需更大样本队列进一步评估。

局限性

  • 原文未报告局限性。
  • 作者在结论中提出需使用更大样本量的队列进一步评估含整合酶链转移抑制剂方案与妊娠期高血压疾病的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the incidence of hypertensive disorders of pregnancy among women living with human immunodeficiency virus (HIV) on combination antiretroviral therapy (ART) to women without HIV, and to evaluate the association of hypertensive disorders of pregnancy with ART regimens or timing of ART initiation. METHODS: We conducted a retrospective cohort study among two overlapping pregnancy cohorts using preexisting databases at a single tertiary care hospital: all pregnant women who delivered during years 2016-2018 (cohort 1) and all women living with HIV who delivered during years 2011-2018 (cohort 2). The primary outcome for both cohorts was any hypertensive disorder of pregnancy; gestational hypertension and preeclampsia were also examined separately. The primary exposure variables were HIV status for cohort 1 and ART regimen (integrase strand transfer inhibitor-containing, protease inhibitor-containing, or non-nucleoside reverse transcriptase inhibitor-containing) for cohort 2. For estimation of risk ratios (RRs), we used a modified Poisson regression with robust error variances. Multivariate models among the women living with HIV in cohort 2 were tested for a statistical interaction between ART regimen and timing of initiation. RESULTS: In cohort 1, among 80 women living with HIV compared with 3,464 women without HIV, there was no difference in the risk of hypertensive disorders of pregnancy (29% in women living with HIV vs 30% in women without HIV, adjusted RR 0.9, 95% CI 0.6-1.3). In cohort 2, among 265 women living with HIV, integrase strand transfer inhibitor-containing regimens were associated with an increased risk for any hypertensive disorder of pregnancy (25% among integrase strand transfer inhibitor vs 10% among protease inhibitor, adjusted RR 2.8, 95% CI 1.5-5.1) and gestational hypertension (20% among integrase strand transfer inhibitor vs 8% among protease inhibitor, adjusted RR 2.8, 95% CI 1.3-5.9) compared with protease inhibitor-containing regimens. Timing of ART initiation was not associated with hypertensive disorders of pregnancy, nor did it significantly alter the associations between ART regimen and hypertensive disorders of pregnancy outcomes. CONCLUSION: Overall the risk of hypertensive disorders of pregnancy was similar among women living with HIV on ART and women without HIV. With greater integrase strand transfer inhibitor use, the greater frequency of hypertensive disorders of pregnancy with these regimens compared with protease inhibitor-containing regimens warrants future evaluation using cohorts with greater sample size.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Saums MK, King CC, Adams JC, et al. Combination Antiretroviral Therapy and Hypertensive Disorders of Pregnancy. Obstet Gynecol. 2019. PMID: 31764730. doi:10.1097/AOG.0000000000003584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。